Molecular genetics of neurodegenerative dementias

Cold Spring Harbor Perspectives in Biology

Volumn 9, Issue 4, 2017, Pages

  Hinz, Flora I ^a   Geschwind, Daniel H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGENERATIVE DISEASE; DEMENTIA; GENETIC PREDISPOSITION; GENETICS; HUMAN;

DEMENTIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 85017235388     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a023705     Document Type: Article

References (174)

1. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. 2012. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 124: 339-352.
2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding pro-tein 2. Nat Genet 23: 185-188.
3. Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, De-Jesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW III, Rademakers R, et al. 2013. Unconvention-al translation of C9ORF72 GGGGCC expansion gener-ates insoluble polypeptides specific to c9FTD/ALS. Neu-ron 77: 639-646.
4. Ashford JW. 2004. APOE genotype effects on Alzheimer’s disease onset and epidemiology. J Mol Neurosci 23: 157-165.
5. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rade-makers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, et al. 2006. Mutations in pro-granulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442: 916-919.
6. Bang J, Spina S, Miller BL. 2015. Frontotemporal dementia. Lancet 386: 1672-1682.
7. Bartolome F, Wu HC, Burchell VS, Preza E, Wray S, Maho-ney CJ, Fox NC, Calvo A, Canosa A, Moglia C, et al. 2013. Pathogenic VCP mutations induce mitochondrial un-coupling and reduced ATP levels. Neuron 78: 57-64
8. Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, Corneveaux JJ, Hardy J, Vonsattel JP, Younkin SG, et al. 2014. Genome-wide association metaanalysis of neuropathologic features of Alzheimer’s dis-ease and related dementias. PLoS Genet 10: e1004606
9. Bendor JT, Logan TP, Edwards RH. 2013. The function of asynuclein. Neuron 79: 1044-1066.
10. Bennion Callister J, Pickering-Brown SM. 2014. Pathogen-esis/genetics of frontotemporal dementia and how it relates to ALS. Exp Neurol 262: 84-90.
11. Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der Zee J, Sleegers K, Peeters K, Martin JJ, Del-Favero J, et al. 2007. A novel locus for dementia with Lewy bodies: A clinically and genetically heterogeneous disorder. Brain 130: 2277-2291.
12. Bonifati V. 2008. Recent advances in the genetics of demen-tia with lewy bodies. Curr Neurol Neurosci Rep 8: 187-189.
13. Braak H, Braak E. 1997. Diagnostic criteria for neuropath-ologic assessment of Alzheimer’s disease. Neurobiol Aging 18: S85-S88.
14. Braak H, Braak E. 1998. Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Trans Supplementum 53: 127-140.
15. Brandt R, Hundelt M, Shahani N. 2005. Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim Biophys Acta 1739: 331-354
16. Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, et al. 2007. Alzheimer and Parkinson diag-noses in progranulin null mutation carriers in an extend-ed founder family. Arch Neurol 64: 1436-1446.
17. Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, Pickut BA, Van den Broeck M, Mattheijssens M, Peetrs K, et al. 2008. Genetic vari-ability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71: 656-664
18. Brown K, Mastrianni JA. 2010. The prion diseases. J Geriatr Psychiatry Neurol 23: 277-298.
19. Bultema JJ, Ambrosio AL, Burek CL, Di Pietro SM. 2012. BLOC-2, AP-3, and AP-1 proteins function in concert with Rab38 and Rab32 proteins to mediate protein traf-ficking to lysosome-related organelles. J Biol Chem 287: 19550-19563.
20. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. 2011. Human apoE isoforms differ-entially regulate brain amyloid-b peptide clearance. Sci Transl Med 3: 89ra57.
21. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. 2004. a-Synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364: 1167-1169.
22. Chen JA, Wang Q, Davis-Turak J, Li Y, Karydas AM, Hsu SC, Sears RL, Chatzopoulou D, Huang AY, Wojta KJ, et al. 2015. A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and pro-gressive supranuclear palsy. JAMA Neurol 72: 414-422
23. Chow TW, Miller BL, Hayashi VN, Geschwind DH. 1999. Inheritance of frontotemporal dementia. Arch Neurol 7: 817-822.
24. Colombrita C, Onesto E, Megiorni F, Pizzuti A, Baralle FE, Buratti E, Silani V, Ratti A. 2012. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic mes-senger RNAs and differently regulate their post-tran-scriptional fate in motoneuron-like cells. J Biol Chem 287: 15635-15647.
25. Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ, Clarimón J, Lleó A. 2013. Confluence of asynuclein, tau, and b-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72: 1203-1212.
26. Cooper-Knock J, Bury JJ, Heath PR, Wyles M, Higginbot-tom A, Gelsthorpe C, Highley JR, Hautbergue G, Rattray M, Kirby J, et al. 2015. C9ORF72 GGGGCC expanded repeats produce splicing dysregulation which correlates with disease severity in amyotrophic lateral sclerosis. PLoS ONE 10: e0127376.
27. Coppola G, Karydas A, Rademakers R, Wang Q, Baker M, Hutton M, Miller BL, Geschwind DH. 2008. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 64: 92-96.
28. Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, et al. 2012. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer’s diseases. Hum Mol Genet 21: 3500-3512.
29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261: 921-923.
30. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr., RImmler JB, Locke PA, Conneally PM, Schmader KE, et al. 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7: 180-184.
31. Cruchaga C, Kauwe JSK, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D, et al. 2013. GWAS of cerebrospinal fluid tau levels identifies risk var-iants for Alzheimer’s disease. Neuron 78: 256-268.
32. Cruts M, Van Broeckhoven C. 2008. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet 4: 186-194.
33. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghe R, Dermaut B, Martin JJ, et al. 2006. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442: 920-924.
34. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, et al. 2011. Acid b-glucosidase mutants linked to Gaucher disease, Parkin-son disease, and Lewy body dementia alter a-synuclein processing. Ann Neurol 69: 940-953.
35. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, et al. 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72: 245-256.
36. Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rade-makers R, Saerens J, Pickut BA, Peeters K, van den Broeck M, Vennekens K, et al. 2004. A novel presenilin 1 mutation associated with Pick’s disease but not b-amyloid plaques. Ann Neurol 55: 617-626.
37. Eriksen JL, Mackenzie IRA. 2007. Progranulin: Normal function and role in neurodegeneration. J Neurochem 104: 287-297.
38. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr., Ellis MC, Fullan A, et al. 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408.
39. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JBJ, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, et al. 2014. Frontotemporal dementia and its subtypes: A genome-wide association study. Lancet Neurol 13: 686-699.
40. Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Cop-pola G, Dejesus-Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L, et al. 2011. TMEM106B regulates pro-granulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76: 467-474.
41. Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee KH, Badders N, Valentine M, Miller BL, Wong PC, et al. 2015. GGGGCC repeat expansion in C9orf72 compro-mises nucleocytoplasmic transport. Nature 525: 129-133.
42. Frost B, Jacks RL, Diamond MI. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845-12852.
43. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, Schule B, Langston JW, Middleton FA, Ross OA, Hulihan M, et al. 2007. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neu-rology 68: 916-922.
44. Gatz M, Mortimer JA, Fratiglioni L, Johansson B, Berg S, Reynolds CA, Pedersen NL. 2006. Potentially modifiable risk factors for dementia in identical twins. Alzheimer’s Dement 2: 110-117.
45. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, Bullido MJ, Engelborghs S, De Deyn P, Berr C, et al. 2011. APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Mol Psychiatry 16: 903-907.
46. Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. 2015. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathol-ogy and neuroimaging. Neuropathol Appl Neurobiol 41: 24-46.
47. Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, Ivanoiu A, Deryck O, Edbauer D, Zhang M, et al. 2015. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry 21: 1112-1124.
48. Goedert M. 2015. Neurodegeneration. Alzheimer’s and Par-kinson’s diseases: The prion concept in relation to assembled Ab, tau, and a-synuclein. Science 349: 1255555
49. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E. 2006. Glucocere-brosidase mutations are an important risk factor for Lewy body disorders. Neurology 67: 908-910.
50. Grad LI, Fernando SM, Cashman NR. 2015. From molecule to molecule and cell to cell: Prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiol Dis 77: 257-265
51. Guerreiro RJ, Gustafson DR, Hardy J. 2012. The genetic architecture of Alzheimer’s disease: Beyond APP, PSENs and APOE. Neurobiol Aging 33: 437-456.
52. Guo JL, Lee VM. 2011. Seeding of normal tau by patholog-ical tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286: 15317-15331.
53. Guyant-Marechal I, Berger E, Laquerrière A, Rovelet-Lecrux A, Viennet G, Frebourg T, Rumbach L, Campion D, Hannequin D. 2008. Intrafamilial diversity of phenotype as-sociated with app duplication. Neurology 71: 1925-1926
54. Haeusler AR, Donnelly CJ, Periz G, Simko EAJ, Shaw PG, Kim MS, Maragakis NJ, Troncoso JC, Pandey A, Sattler R, et al. 2014. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507: 195-200.
55. Hardy JA, Higgins GA. 1992. Alzheimer’s disease: The amyloid cascade hypothesis. Science 256: 184-185
56. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Wi-lliams A, et al. 2009. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41: 1088-1093.
57. Hästbacka J, de la Chapelle A, Mahtani MM, Clines G, Reeve-Daly MP, Daly M, Hamilton BA, Kusumi K, Tri-vedi B, Weaver A, et al. 1994. The diastrophic dysplasia gene encodes a novel sulfate transporter: Positional clon-ing by fine-structure linkage disequilibrium mapping. Cell 78: 1073-1087.
58. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are asso-ciated with Alzheimer’s disease. Nat Genet 43: 429-435
59. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. 2014. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci 111: E4376-E4385
60. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. 1998. Association of missense and 50-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705.
61. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between a-synuclein gene duplication and familial Par-kinson’s disease. Lancet 364: 1169-1171.
62. Ishikawa A, Piao YS, Miyashita A, Kuwano R, Onodera O, Ohtake H, Suzuki M, Nishizawa M, Takahashi H. 2005. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer’s disease. Ann Neurol 57: 429-434
63. Janssens J, Van Broeckhoven C. 2013. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet 22: R77-R87.
64. Jiao J, Herl LD, Farese RV, Gao FB. 2010. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal de-mentia. PLoS ONE 5: e10551.
65. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al. 2012. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488: 96-99.
66. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. 2013. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med 368: 107-116.
67. Jovičic´ A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW 3rd, Sun S, Herdy JR, Bieri G, et al. 2015. Modifiers of C9orf72 dipeptide repeat toxicity con-nect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci 18: 1226-1229.
68. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. 2008. TARDBP mutations in individ-uals with sporadic and familial amyotrophic lateral scle-rosis. Nat Genet 40: 572-574.
69. Kara E, Ling H, Pittman AM, Shaw K, de Silva R, Simone R, Holton JL, Warren JD, Rohrer JD, Xiromerisiou G, et al. 2012. The MAPT p.A152T variant is a risk factor associ-ated with tauopathies with atypical clinical and neuro-pathological features. Neurobiol Aging 33: 2231e7-2231e14.
70. Karch CM, Goate AM. 2015. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77: 43-51.
71. Karch CM, Cruchaga C, Goate AM. 2014. Alzheimer’s disease genetics: From the bench to the clinic. Neuron 83: 11-26
72. Karran E, Mercken M, De Strooper B. 2011. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
73. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. 1989. Identification of the cystic fibrosis gene: Genetic analysis. Sci-ence 245: 1073-1080.
74. Kim J, Basak JM, Holtzman DM. 2009. The role of apolipo-protein E in Alzheimer’s disease. Neuron 63: 287-303
75. Kleinberger G, Capell A, Haass C, Van Broeckhoven C. 2013. Mechanisms of granulin deficiency: Lessons from cellular and animal models. Mol Neurobiol 47: 337-360.
76. Kohli MA, John-Williams K, Rajbhandary R, Naj A, Whitehead P, Hamilton K, Carney RM, Wright C, Crocco E, Gwirtzman HE, et al. 2013. Repeat expansions in the C9ORF72 gene contribute to Alzheimer’s disease in Cau-casians. Neurobiol Aging 34: 1519.e5-12.
77. Kovács GG, Puopolo M, Ladogana A, Pocchiari M, Budka H, van Duijn C, Collins SJ, Boyd A, Giulivi A, Coulthart M, et al. 2005. Genetic prion disease: The EUROCJD experience. Hum Genet 118: 166-174.
78. Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, Woitalla D, Portman AT, Maguire RP, Veenma L, Schröder U, et al. 2001. Familial parkinsonism with synuclein pa-thology: Clinical and PET studies of A30P mutation car-riers. Neurology 56: 1355-1362.
79. Labbé C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, et al. 2015. Role for the micro-tubule-associated protein tau variant p.A152T in risk of a-synucleinopathies. Neurology 85: 1680-1686.
80. Laird AS, Van Hoecke A, De Muynck L, Timmers M, Van den Bosch L, Van Damme P, Robberecht W. 2010. Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 5: e13368.
81. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Taver-nier B, et al. 2009. Genome-wide association study iden-tifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41: 1094-1099.
82. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. 2013. Meta-analysis of 74,046 in-dividuals identifies 11 new susceptibility loci for Alz-heimer’s disease. Nat Genet 45: 1452-1458.
83. Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D, Capell A, Haass C. 2012. Membrane orientation and subcellular localization of transmembrane pro-tein 106B (TMEM106B), a major risk factor for fronto-temporal lobar degeneration. J Biol Chem 287: 19355-19365.
84. Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Péchoux S, Camuzat A, Clot F, Fenoglio C; French research network on FTD and FTD-ALS, Scarpini E, et al. 2014. Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neuro-biol Aging 35: 2658e1-2658e5.
85. Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, Troakes C, Nishimura AL, Scotter EL, Vance C, et al. 2013. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep 5: 1178-1186.
86. Levine TP, Daniels RD, Gatta AT, Wong LH, Hayes MJ. 2013. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 29: 499-503.
87. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. 2013. Apolipo-protein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9: 106-118.
88. Liu Y, Yu JT, Zong Y, Zhou J, Tan L. 2014. C9ORF72 muta-tions in neurodegenerative diseases. Mol Neurobiol 49: 386-398.
89. Lord J, Lu AJ, Cruchaga C. 2014. Identification of rare var-iants in Alzheimer’s disease. Front Genet 5: 369.
90. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971-983
91. Mahley RW. 1988. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
92. Majounie E, Abramzon Y, Renton AE, Perry R, Bassett SS, Pletnikova O, Troncoso JC, Hardy J, Singleton AB, Traynor BJ. 2012a. Repeat expansion in C9ORF72 in Alz-heimer’s disease. N Engl J Med 366: 283-284.
93. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chiò A, Restagno G, Nicolaou N, Simon-San-chez J, et al. 2012b. Frequency of the C9orf72 hexanucleo-tide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol 11: 323-330.
94. Mastrianni JA. 2010. The genetics of prion diseases. Gen Med 12: 187-195.
95. Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, et al. 2009a. Genetic risk factors for variant Creutzfeldt-Jakob disease: A genome-wide association study. Lancet Neurol 8: 57-66.
96. Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Dujaily H, Hummerich H, Beck J, Mein CA, et al. 2009b. A novel protective prion protein variant that co-localizes with kuru exposure. N Engl J Med 361: 2056-2065.
97. Meeus B, Theuns J, Van Broeckhoven C. 2012. The genetics of dementia with Lewy bodies: What are we missing? Arch Neurol 69: 1113-1118.
98. Mentula HK, Tuovinen L, Penttilä S, Suominen T, Udd B, Palmio J. 2012. TARDBP mutations are not a frequent cause of ALS in Finnish patients. Acta Myologica 31: 134-138.
99. Miller ZA, Sturm VE, Camsari GB, Karydas A, Yokoyama JS, Grinberg LT, Boxer AL, Rosen HJ, Rankin KP, Gorno-Tempini ML, et al. 2016. Increased prevalence of autoim-mune disease within C9 and FTD/MND cohorts: Com-pleting the picture. Neurol Neuroimmunol Neuroinflamm 6: 301.
100. Miyashita A, Koike A, Jun G, Wang LS, Takahashi S, Matsu-bara E, Kawarabayashi T, Shoji M, Tomita N, Arai H, et al. 2013. SORL1 is genetically associated with late-onset Alz-heimer’s disease in Japanese, Koreans and Caucasians. PLoS ONE 8: e58618.
101. Molano JRV. 2013. Dementia with Lewy bodies. Semin Neu-rol 33: 330-335.
102. Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. 2013. The C9orf72 GGGGCC re-peat is translated into aggregating dipeptide-repeat pro-teins in FTLD/ALS. Science 339: 1335-1338.
103. Morris HR, Khan MN, Janssen JC, Brown JM, Perez-Tur J, Baker M, Ozansoy M, Hardy J, Hutton M, Wood NW, et al. 2001. The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 58: 1813-1816.
104. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, et al. 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43: 436-441.
105. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, Shaffer T, Wong M, Bhattacharjee A, Eichler EE, et al. 2009. Targeted capture and massively parallel sequenc-ing of 12 human exomes. Nature 461: 272-276.
106. Ng ASL, Rademakers R, Miller BL. 2015. Frontotemporal dementia: A bridge between dementia and neuromuscu-lar disease. Ann NY Acad Sci 1338: 71-93.
107. Ohtake H, Limprasert P, Fan Y, Onodera O, Kakita A, Taka-hashi H, Bonner LT, Tsuang DW, Murray IV, Lee VM, et al. 2004. b-synuclein gene alterations in dementia with Lewy bodies. Neurology 63: 805-811.
108. Oueslati A, Ximerakis M, Vekrellis K. 2014. Protein trans-mission, seeding and degradation: Key steps for a-synu-clein prion-like propagation. Exp Neurobiol 23: 324-336.
109. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, et al. 1999. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 sub-jects. Ann Neurol 46: 224-233.
110. Peggion C, Sorgato MC, Bertoli A. 2014. Prions and prion-like pathogens in neurodegenerative disorders. Pathogens 3: 149-163.
111. Petkau TL, Leavitt BR. 2014. Progranulin in neurodegener-ative disease. Trends Neurosci 37: 388-398.
112. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. 1998. Tau is a candidate gene for chro-mosome 17 frontotemporal dementia. Ann Neurol 43: 815-825.
113. Prince M, Albanese E, Guerchet M, Prina M. 2014. World Alzheimer report 2014. Dementia and risk reduction: An analysis of protective and modifiable factors. Alzheimer’s Disease International, London. https://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf.
114. Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston AE, Desaro P, et al. 2015. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci 18: 1175-1182.
115. Prusiner SB. 2012. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336: 1511-1513.
116. Prusiner SB. 2013. Biology and genetics of prions causing neurodegeneration. Ann Rev Genet 47: 601-623
117. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, et al. 2015. Evidence for -synuclein prions causing mul-tiple systems atrophy in humans with parkinsonism. Prot Natl Acad Sci 38: E5308-E5317.
118. Rademakers R, Rovelet-Lecrux A. 2009. Recent insights into the molecular genetics of dementia. Trends Neurosci 32: 451-461.
119. Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, Goate A, van Broeckhoven C. 2003. Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Hum Mutat 22: 409-411.
120. Rademakers R, Cruts M, van Broeckhoven C. 2004. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24: 277-295.
121. Rademakers R, Neumann M, Mackenzie IR. 2012. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8: 423-434.
122. Reitz C, Jun G, Naj A, Rajbhandary R, Vardarajan BN, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, et al. 2013. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 14,and the risk of lateonset Alzheimer disease in African Americans. JAMA 309: 1483-1492.
123. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rol-linson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257-268.
124. Riedl L, Mackenzie IR, Förstl H, Kurz A, Diehl-Schmid J. 2014. Frontotemporal lobar degeneration: Current perspectives. Neuropsychiatr Dis Treat 10: 297-310
125. Riudavets MA, Bartoloni L, Troncoso JC, Pletnikova O, St George-Hyslop P, Schultz M, Sevlever G, Allegri RF. 2013. Familial dementia with frontotemporal features associat-ed with M146V presenilin-1 mutation. Brain Pathol 23: 595-600.
126. Robinson A, Davidson Y, Snowden JS, Mann DMA. 2014. C9ORF72 in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 85: 1435-1436.
127. Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, et al. 2009. The heritability and genetics of frontotemporal lobar degeneration. Neurology 73: 1451-1456.
128. Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, Winden KD, Oldham MC, Martens LH, Zhou P, Farese RV Jr., et al. 2011. Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71: 1030-1042.
129. Rosenthal SL, Kamboh MI. 2014. Lateonset Alzheimer’s disease genes and the potentially implicated pathways. Curr Genet Med Rep 2: 85-101.
130. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, et al. 2008. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 4: e1000193.
131. Ryan CL, Baranowski DC, Chitramuthu BP, Malik S, Li Z, Cao M, Minotti S, Durham HD, Kay DG, Shaw CA, et al. 2009. Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci 10: 130
132. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, et al. 2014. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82: 1271-1288
133. Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, de Koning I, Maat-Kievit JA, Anar B, Donker Kaat L, Breedveld GJ, et al. 2008. Distinct genetic forms of fron-totemporal dementia. Neurology 71: 1220-1226.
134. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 1: a006189.
135. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gud-nason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, et al. 2010. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-1840.
136. Sheng J, Su L, Xu Z, Chen G. 2014. Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer’s disease. Gene 542: 141-145
137. Shibuya S, Higuchi J, Shin RW, Tateishi J, Kitamoto T. 1998. Protective prion protein polymorphisms against sporadic Creutzfeldt-Jakob disease. Lancet 351: 419
138. Sieben A, Van Langenhove T, Engelborghs S, Martin JJ, Boon P, Cras P, De Deyn PP, Santens P, Van Broeckhoven C, Cruts M. 2012. The genetics and neuropathology of fron-totemporal lobar degeneration. Acta Neuropathol 124: 353-372.
139. Singleton AB. 2011. Exome sequencing: A transformative technology. Lancet Neurol 10: 942-946.
140. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. 2003. a-Synuclein locus triplication causes Parkinson’s disease. Science 302: 841.
141. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, et al. 2005. Mutations in the endo-somal ESCRTIII-complex subunit CHMP2B in fronto-temporal dementia. Nat Genet 37: 806-808.
142. Smethurst P, Sidle KCL, Hardy J. 2015. Review: Prion-like mechanisms of transactive response DNA binding pro-tein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol Appl Neurobiol 41: 578-597.
143. Spillantini MG, Goedert M. 2013. Tau pathology and neurodegeneration. Lancet Neurol 12: 609-622.
144. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci 95: 7737-7741.
145. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668-1672.
146. Stöhr J, Condello C, Watts JC, Bloch L, Oehler A, Nick M, DeArmond SJ, Giles K, DeGrado WF, Prusiner SB. 2014. Distinct synthetic Ab prion strains producing different amyloid deposits in bigenic mice. Proc Natl Acad Sci 111: 10329-10334.
147. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Sal-vesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993. Binding of human apoli-poprotein E to synthetic amyloid b peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci 90: 8098-8102.
148. Takada LT, Geschwind MD. 2013. Prion diseases. Semin Neurol 33: 348-356.
149. Tanikawa S, Mori F, Tanji K, Kakita A, Takahashi H, Waka-bayashi K. 2012. Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplas-mic inclusions in a-synucleinopathy. Neurosci Lett 527: 16-21.
150. Thinakaran G, Koo EH. 2008. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283: 29615-29619.
151. Toh H, Chitramuthu BP, Bennett HPJ, Bateman A. 2011. Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci 45: 538-548
152. Tran H, Almeida S, Moore J, Gendron TF, Chalasani U, Lu Y, Du X, Nickerson JA, Petrucelli L, Weng Z, et al. 2015. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ ALS. Neuron 87: 1207-1214.
153. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, et al. 2012. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathol-ogy. Neurology 79: 1944-1950.
154. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, et al. 2013. APOE 14 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70: 223-228.
155. Valdmanis PN, Daoud H, Dion PA, Rouleau GA. 2009. Re-cent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 9: 198-205.
156. van Blitterswijk M, Rademakers R. 2015. Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport. Nat Rev Neurol 11: 670-672.
157. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W. 2008. Progranulin functions as a neuro-trophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181: 37-41.
158. van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J, et al. 2011. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134: 808-815
159. Vann Jones SA, O’Brien JT. 2014. The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol Med 44: 673-683.
160. Visscher PM, Brown MA, McCarthy MI, Yang J. 2012. Five years of GWAS discovery. Am J Hum Genet 90: 7-24
161. Waite AJ, Bäumer D, East S, Neal J, Morris HR, Ansorge O, Blake DJ. 2014. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and fron-totemporal degeneration brain with the C9ORF72 hex-anucleotide repeat expansion. Neurobiol Aging 35: 1779e5-1779e13.
162. Wang CSM, Burke JR, Steffens DC, Hulette CM, Breitner JCS, Plassman BL. 2009. Twin pairs discordant for neuropathologically confirmed Lewy body dementia. J Neurol Neurosurg Psychiatry 80: 562-565.
163. Wang WX, Wilfred BR, Madathil SK, Tang G, Hu Y, Di-mayuga J, Stromberg AJ, Huang Q, Saatman KE, Nelson PT. 2010. miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegen-erative disease. Am J Pathol 177: 334-345.
164. Wang Z, Liu X, Yang BZ, Gelernter J. 2013. The role and challenges of exome sequencing in studies of human diseases. Front Genet 4: 160.
165. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Dar-vish D, Pestronk A, Whyte MP, Kimonis VE. 2004. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36: 377-381.
166. Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB. 2014. Serial propagation of distinct strains of Ab prions from Alzheimer’s disease patients. Proc Natl Acad Sci 111: 10323-10328.
167. Wilquet V, De Strooper B. 2004. Amyloid-b precursor pro-tein processing in neurodegeneration. Curr Opin Neurobiol 14: 582-588.
168. Wojciechowska M, Krzyzosiak WJ. 2011. Cellular toxicity of expanded RNA repeats: Focus on RNA foci. Hum Mol Genet 20: 3811-3821.
169. Wojtas A, Heggeli KA, Finch N, Baker M, DeJesus-Her-nandez M, Younkin SG, Dickson DW, Graff-Radford NR, Rademakers R. 2012. C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. Am J Neurodegener Dis 1: 107-118.
170. Yamaguchi K, Cochran EJ, Murrell JR, Polymeropoulos MH, Shannon KM, Crowther RA, Goedert M, Ghetti B. 2005. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the a-synuclein gene. Acta Neuropa-thol 110: 298-305.
171. Yamanaka K, Sasagawa Y, Ogura T. 2012. Recent advances in pp97/VCP/Cdc48 cellular functions. Biochim Biophys Acta 1823: 130-137.
172. Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Stein-bart E, Galloway NM, Feldman H, Woltjer R, Miller CA, et al. 2010. The spectrum of mutations in progranulin: A collaborative study screening 545 cases of neurodegener-ation. Arch Neurol 67: 161-170.
173. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, et al. 2004. The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
174. Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. 2015. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525: 56-61